Posted on 15/02/2010 in Medical Company Financials Boston Scientific has experienced an improvement in sales revenues during the last quarter of 2009, according to the company's most recent financial breakdown.
The medical company's net sales for the full year came to $2.07 billion (1.32 billion pounds), which represents a minor increase on the $2 billion figure recorded during 2008.
It stated that the company's strong performance is attributable to the growth of sales in sectors such as endoscopy, urology and neuromodulation, as well as the launch of products such as the Promus everolimus-eluting coronary stent system.
The firm also highlighted its continued leadership of the global drug-eluting stent market, in which it holds a share of 39 per cent.
Ray Elliott, president and chief executive officer of Boston Scientific, said: "We delivered a quarter in line with expectations, coming in at the middle of our sales range and the high end of our adjusted earnings range."
The firm also revealed this month that it will be making management changes and conducting restructuring initiatives in the coming year in order to increase profitability.Other news stories from 15/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
